Elsevier

Gynecologic Oncology

Volume 51, Issue 1, October 1993, Pages 104-108
Gynecologic Oncology

Regular Article
Ifosfamide and Mesna in Epithelial Ovarian Carcinoma

https://doi.org/10.1006/gyno.1993.1254Get rights and content

Abstract

Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s. Because of significant urothelial toxicity, phase II studies in ovarian cancer in this country were delayed until the urinary epithelial protector mesna became available in 1985. Since that time, two well-executed prospective trials have shown that this agent produces measurable responses in about 20% of women with ovarian epithelial cancer recurring after primary chemotherapy and in 12% of those with tumors refractory to first-line therapy with regimens including cisplatin. Toxicity includes moderate to severe hematologic toxicity, renal dysfunction which is usually reversible, and CNS abnormalities including lethargy, somnolence, and disorientation. The risk of toxicity may be increased in patients with compromised hepatic or renal function and in those with hydronephrosis or hypoalbuminemia.

References (0)

Cited by (16)

  • Epithelial ovarian cancer

    2018, Clinical Gynecologic Oncology
  • Epithelial Ovarian Cancer

    2012, Clinical Gynecologic Oncology: Eighth Edition
  • Management of Recurrent Ovarian Carcinoma: Current Status and Future Directions

    2009, Seminars in Oncology
    Citation Excerpt :

    The decision of whether and when to use oral etoposide is influenced by the degree of gastrointestinal complications caused by the patient's cancer as she must be able to tolerate oral therapy in order to have a chance of benefit from this agent. Vinorelbine,60-62 cyclophosphamide, ifosfamide,63,64 and melphalan65 also have been used to treat recurrent disease, with response rates ranging from 10% to 20%, and these drugs may be considered for those patients who have continued relative sensitivity to chemotherapy and have received the more commonly used agents. Hexamethylmelamine (RR, 10%-17%)66-71 is an oral agent that is approved for the treatment of patients with recurrent ovarian carcinoma, although its use is limited by gastrointestinal toxicity.

  • Epithelial Ovarian Cancer

    2007, Clinical Gynecologic Oncology
  • Synthesis and evaluation of Taxol-folic acid conjugates as targeted antineoplastics

    2002, Bioorganic and Medicinal Chemistry
    Citation Excerpt :

    The first two lines express high levels of the folate receptor.22 The A549 cell line, however, expresses negligible levels of functional folate receptors.23 With the exception of Taxol 14 being uniformly more potent, little difference was seen with respect to folate receptor involvement (Fig. 3).

View all citing articles on Scopus
View full text